Clinical Trials Sponsored by 3D Medicines

Total 13909 results

3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
3D Medicines (Beijing) Co., Ltd.

Withdrawn

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
3D Medicines

Not yet recruiting

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Cancer Pain
3D Medicines

Active, not recruiting

Study of 3D189 in Patients With Hematologic Malignancies

Multiple Myeloma | Non-Hodgkin Lymphoma | Acute Leukemia | Higher-risk Myelodysplastic Syndrome

China
3D Medicines

Completed

Phase 1 Study of 3D229 in Healthy Subjects

Healthy Subject

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
3D Medicines (Beijing) Co., Ltd.

Not yet recruiting

Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma,Adult
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase I Trial of Envafolimab for Healthy Male Subjects

Healthy Male

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

KN035 for dMMR/MSI-H Advanced Solid Tumors

Solid Tumor

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
3D Medicines (Beijing) Co., Ltd.

Active, not recruiting

A Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China, United States
Shanghai Chest Hospital
3D Medicines

Not yet recruiting

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Non-Small Cell Lung Cancer
Peking Union Medical College Hospital
3D Medicines

Unknown

Precise Treatment in Hepatobiliary Cancers (PTHBC) (PTHBC)

Liver Neoplasms | Biliary Tract Neoplasms | Hepatobiliary Neoplasms

China
3D Therapy, LLC

Completed

The Feasibility of VR for OUD

Opioid Use Disorder

United States
3D Metal Printing Ltd
University of Bath

Unknown

TOKA: Custom Made Devices for High Tibial Osteotomy (HTO) - Clinical Investigation (TOKA)

Unicompartmental Medial Knee Osteoarthritis

Italy
University of Toronto
Toronto 3D Knowledge Synthesis and Clinical Trials foundation

Unknown

Meta-analyses of Pasta as Part of Low Glycemic Index Diets and Adiposity

Obesity | Cardiovascular Disease | Diabetes | Overweight | Metabolic Syndrome | Prediabetes
University of Bath
University of Oxford; 3D Metal Printing Ltd; Versus Arthritis

Recruiting

Personalised Against Standard High Tibial Osteotomy (PASHiOn)

Medial Knee Osteoarthritis

United Kingdom
Chongqing University Cancer Hospital
Zhejiang Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and other collaborators

Completed

Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test

Epithelial Ovarian Cancer | Adnexal Mass

China
Medicines for Malaria Venture
Institute of Tropical Medicine, University of Tuebingen

Completed

DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

Plasmodium Falciparum, Malaria

Germany
Totus Medicines

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Cervical Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | HER2-negative Breast Cancer

United States
Pfizer
London School of Hygiene and Tropical Medicine; Medicines for Malaria Venture

Terminated

Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa

Intermittent Preventive Treatment In Pregnancy (IPTp)

Malawi, Benin, Kenya, Tanzania, Uganda
Tenet Medicines

Terminated

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis | Minimal Change Disease

United States
Tenet Medicines

Active, not recruiting

Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

Membranous Nephropathy

United States
Pfizer
Biostatistics, Preventive Medicinte Department, College of Medicine, Yonsei...

Completed

Rheumatoid Arthritis Satisfaction Outcome Research

Rheumatoid Arthritis

Korea, Republic of
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Zhejiang Co., Ltd.

Active, not recruiting

Study of LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

China
Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States, Puerto Rico
Praxis Precision Medicines

Recruiting

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Essential Tremor

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Praxis Precision Medicines

Recruiting

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) (EMBOLD)

SCN2A Encephalopathy | SCN8A Encephalopathy

United States, Spain
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Blueprint Medicines Corporation

Recruiting

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid Neoplasm

United States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
TYK Medicines, Inc

Recruiting

A Study of TY-302 in Patients With Advanced Solid Tumors

Breast Cancer | Solid Tumor

China
Praxis Precision Medicines

Completed

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

Epilepsy | SCN2A-DEE

United States
Praxis Precision Medicines

Active, not recruiting

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Epilepsy | SCN2A-DEE

United States
The Medicines Company

Completed

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Acute Bacterial Skin and Skin Structure Infection

United States
LaNova Medicines Limited

Withdrawn

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Relapsed or Refractory Multiple Myeloma | Other Plasma Cell Diseases
LaNova Medicines Limited

Terminated

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

United States
LaNova Medicines Limited

Terminated

Study of LM-061 in Subjects in Advanced Tumors

Advanced Tumours

Australia
Homology Medicines, Inc

Terminated

Natural History Clinical Study in Adult PKU

Phenylketonurias | PKU

United States
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Blueprint Medicines Corporation

Active, not recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

Canada, United States, Spain, United Kingdom, Germany, Belgium, Switzerland, Italy, Netherlands, Denmark, France, Norway, Sweden
Blueprint Medicines Corporation

Completed

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Relapsed or Refractory Myeloid Malignancies

United States, United Kingdom
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China

Clinical Trials Sponsored by 3D Medicines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations